Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Characteristic Clodronate (n = 530) Placebo (n = 539)
Mean age ± SD (years) 52.8 ± 10.6 52.7 ± 10.5
Mean BMI ± SD (kg/m2) 25.8 ± 4.5 25.8 ± 4.8
Menopausal status (n)   
   Premenopausal 265 (50%) 265 (49%)
   Postmenopausal 265 (50%) 274 (51%)
Axillary lymph node involvement (n) 196 (37%) 202 (38%)
Tumor stage (n)   
   I 137 (26%) 143 (26%)
   II 304 (57%) 305 (57%)
   III 48 (9%) 52 (10%)
   Unclassifiable 40 (8%) 39 (7%)
   Missing 1 (0.2%) 0 (0%)
Hormone receptor status (n)   
   Oestrogen receptor-positive 245 (46%) 240 (45%)
   Oestrogen receptor-negative 136 (26%) 136 (25%)
   Oestrogen receptor-unknown 149 (28%) 163 (30%)
   Progesterone receptor-positive 112 (21%) 116 (22%)
   Progesterone receptor-negative 79 (15%) 75 (14%)
   Progesterone receptor-unknown 339 (64%) 348 (65%)
  1. BMI, body mass index; SD, standard deviation.